Thus, these results suggest that p53 status may have a role in modulating PXR effects on colon cancer growth and interindividual variability in response to chemotherapeutic drugs, particularly those that elicit p53-mediated signaling. This evidence concerns the gene NR1I2 and malignant colon neoplasm.